BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 20947507)

  • 21. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
    Lenz G; Davis RE; Ngo VN; Lam L; George TC; Wright GW; Dave SS; Zhao H; Xu W; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Chan WC; Staudt LM
    Science; 2008 Mar; 319(5870):1676-9. PubMed ID: 18323416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
    Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
    Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
    Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
    Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.
    Nogai H; Wenzel SS; Hailfinger S; Grau M; Kaergel E; Seitz V; Wollert-Wulf B; Pfeifer M; Wolf A; Frick M; Dietze K; Madle H; Tzankov A; Hummel M; Dörken B; Scheidereit C; Janz M; Lenz P; Thome M; Lenz G
    Blood; 2013 Sep; 122(13):2242-50. PubMed ID: 23869088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
    Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
    Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
    Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
    Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.
    Dong G; Chanudet E; Zeng N; Appert A; Chen YW; Au WY; Hamoudi RA; Watkins AJ; Ye H; Liu H; Gao Z; Chuang SS; Srivastava G; Du MQ
    Clin Cancer Res; 2011 Mar; 17(6):1440-51. PubMed ID: 21266526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
    Lam LT; Davis RE; Ngo VN; Lenz G; Wright G; Xu W; Zhao H; Yu X; Dang L; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20798-803. PubMed ID: 19104039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
    Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
    Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
    Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
    Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain.
    Lamason RL; McCully RR; Lew SM; Pomerantz JL
    Biochemistry; 2010 Sep; 49(38):8240-50. PubMed ID: 20799731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.
    Jattani RP; Tritapoe JM; Pomerantz JL
    J Biol Chem; 2016 Apr; 291(16):8338-48. PubMed ID: 26884334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.
    Gamboa-Cedeño AM; Castillo M; Xiao W; Waldmann TA; Ranuncolo SM
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1437-1448. PubMed ID: 30941572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
    Montesinos-Rongen M; Schmitz R; Brunn A; Gesk S; Richter J; Hong K; Wiestler OD; Siebert R; Küppers R; Deckert M
    Acta Neuropathol; 2010 Oct; 120(4):529-35. PubMed ID: 20544211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cooperative Control of Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling by an Unusual Array of Redundant Repressive Elements.
    Jattani RP; Tritapoe JM; Pomerantz JL
    J Biol Chem; 2016 Apr; 291(16):8324-36. PubMed ID: 26884335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gain-of-function mutations in CARD11 promote enhanced aggregation and idiosyncratic signalosome assembly.
    Stinson JR; Dorjbal B; McDaniel DP; David L; Wu H; Snow AL
    Cell Immunol; 2020 Jul; 353():104129. PubMed ID: 32473470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.